摘要
心力衰竭是各种心血管疾病的终末阶段,尽管目前以抑制交感神经和肾素-血管紧张素-醛固酮系统为基础的药物延缓了疾病的进展,但心力衰竭患者的预后仍不理想。可溶性鸟苷酸环化酶激动剂维立西呱是一种治疗心力衰竭的新型药物,其主要作用于一氧化氮-可溶性鸟苷酸环化酶-环磷酸鸟苷信号通路。现对可溶性鸟苷酸环化酶激动剂维立西呱在心力衰竭领域的最新研究进展做一综述。
Heart failure is the end stage of various cardiovascular diseases.Although drugs based on inhibiting the sympathetic nervous system and renin-angiotensin-aldosterone system have delayed the progression of the disease,the prognosis of heart failure patients is still not ideal.Soluble guanylate cyclase stimulator vericiguat is a novel drug for the treatment of heart failure,which mainly acts on the nitric oxide-soluble guanylate cyclase-cyclic guanosine monophosphate signaling pathway.A review of the latest research progress of the soluble guanylate cyclase stimulator vericiguat in the field of heart failure is presented.
作者
田师鹏
安慧
陈淑霞
谷剑
王立立
TIAN Shipeng;AN Hui;CHEN Shuxia;GU Jian;WANG Lili(Department of Cardiology,Hebei General Hospital,Shijiazhuang 050051,Hebei,China)
出处
《心血管病学进展》
CAS
2023年第7期602-606,共5页
Advances in Cardiovascular Diseases
基金
2022年度河北省引进留学人才资助项目(361003)。
